Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights

EAU Section of Oncological Urology (ESOU) Board

doi:10.1016/j.euo.2021.08.003

Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights

EAU Section of Oncological Urology (ESOU) Board

Résultats de recherche: Contribution à un journal › Article › Revue par des pairs

14 Citations (Scopus)

Résumé

This clinical case-based discussion focuses on a 73-yr-old man diagnosed with intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with systemic therapy. Current guideline-based treatment options are presented and critically examined. The discussion covers the main aspects of the management of metastatic RCC, such as the role of cytoreductive nephrectomy and metastasis-directed therapies, as well as the multiple options for systemic targeted and immune therapies. An insight into developments that may play a role in treatment pathways in the future according to the latest scientific advances is also provided. PATIENT SUMMARY: A number of treatment options are available for patients who have metastatic disease when diagnosed with clear-cell kidney cancer. Starting from a clinical case, the current standard of care and future perspectives regarding treatment of this disease are presented.

langue originale	Anglais
Pages (de - à)	125-133
Nombre de pages	9
journal	European urology oncology
Volume	5
Numéro de publication	1
Les DOIs	https://doi.org/10.1016/j.euo.2021.08.003
état	Publié - 1 févr. 2022

Accès au document

10.1016/j.euo.2021.08.003

Autres fichiers et liens

Lien vers la publication dans Scopus

Contient cette citation

@article{7dc00a54dcbb4cd3a75c9433e1979125,

title = "Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma: Current Recommendations and Future Insights",

abstract = "This clinical case-based discussion focuses on a 73-yr-old man diagnosed with intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with systemic therapy. Current guideline-based treatment options are presented and critically examined. The discussion covers the main aspects of the management of metastatic RCC, such as the role of cytoreductive nephrectomy and metastasis-directed therapies, as well as the multiple options for systemic targeted and immune therapies. An insight into developments that may play a role in treatment pathways in the future according to the latest scientific advances is also provided. PATIENT SUMMARY: A number of treatment options are available for patients who have metastatic disease when diagnosed with clear-cell kidney cancer. Starting from a clinical case, the current standard of care and future perspectives regarding treatment of this disease are presented.",

keywords = "Guidelines, Immunotherapy, Kidney cancer, Metastasis, Nephrectomy, Radiation therapy, Recommendations, Renal cell carcinoma, Targeted therapy",

author = "{EAU Section of Oncological Urology (ESOU) Board} and Daniel Benamran and Laurence Albiges and Axel Bex and Gianluca Giannarini and Umberto Capitanio and Morgan Roupr{\^e}t",

year = "2022",

month = feb,

day = "1",

doi = "10.1016/j.euo.2021.08.003",

language = "English",

volume = "5",

pages = "125--133",

journal = "European urology oncology",

issn = "2588-9311",

number = "1",

}

TY - JOUR

T1 - Treatment Options for De Novo Metastatic Clear-cell Renal Cell Carcinoma

T2 - Current Recommendations and Future Insights

AU - EAU Section of Oncological Urology (ESOU) Board

AU - Benamran, Daniel

AU - Albiges, Laurence

AU - Bex, Axel

AU - Giannarini, Gianluca

AU - Capitanio, Umberto

AU - Rouprêt, Morgan

PY - 2022/2/1

Y1 - 2022/2/1

N2 - This clinical case-based discussion focuses on a 73-yr-old man diagnosed with intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with systemic therapy. Current guideline-based treatment options are presented and critically examined. The discussion covers the main aspects of the management of metastatic RCC, such as the role of cytoreductive nephrectomy and metastasis-directed therapies, as well as the multiple options for systemic targeted and immune therapies. An insight into developments that may play a role in treatment pathways in the future according to the latest scientific advances is also provided. PATIENT SUMMARY: A number of treatment options are available for patients who have metastatic disease when diagnosed with clear-cell kidney cancer. Starting from a clinical case, the current standard of care and future perspectives regarding treatment of this disease are presented.

AB - This clinical case-based discussion focuses on a 73-yr-old man diagnosed with intermediate-risk oligometastatic clear-cell renal cell carcinoma (RCC) and treated with systemic therapy. Current guideline-based treatment options are presented and critically examined. The discussion covers the main aspects of the management of metastatic RCC, such as the role of cytoreductive nephrectomy and metastasis-directed therapies, as well as the multiple options for systemic targeted and immune therapies. An insight into developments that may play a role in treatment pathways in the future according to the latest scientific advances is also provided. PATIENT SUMMARY: A number of treatment options are available for patients who have metastatic disease when diagnosed with clear-cell kidney cancer. Starting from a clinical case, the current standard of care and future perspectives regarding treatment of this disease are presented.

KW - Guidelines

KW - Immunotherapy

KW - Kidney cancer

KW - Metastasis

KW - Nephrectomy

KW - Radiation therapy

KW - Recommendations

KW - Renal cell carcinoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=85121633083&partnerID=8YFLogxK

U2 - 10.1016/j.euo.2021.08.003

DO - 10.1016/j.euo.2021.08.003

M3 - Article

C2 - 34531172

AN - SCOPUS:85121633083

SN - 2588-9311

VL - 5

SP - 125

EP - 133

JO - European urology oncology

JF - European urology oncology

IS - 1

ER -